A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess whether basal cell carcinoma (BCC) lesions
surgically treated with curettage, followed by imiquimod 5% cream as postsurgical adjuvant
therapy, will have an improved cure rate over the ED/C historical norm of approximately 70%
at 1-year posttreatment follow-up. A secondary objective is to assess cosmetic outcome.